Coencapsulated doxorubicin and bromotetrandrine lipid nanoemulsions in reversing multidrug resistance in breast cancer in vitro and in vivo

Molecular Pharmaceutics

Volumn 12, Issue 1, 2015, Pages 274-286

  Cao, Xi ^a   Luo, Jingwen ^a   Gong, Tao ^a   Zhang, Zhi Rong ^a   Sun, Xun ^a   Fu, Yao ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

biodistribution; doxorubicin; lipid nanoemulsions; multidrug resistance; P glycoprotein inhibitor; pharmacokinetics

Indexed keywords

BROMOTETRANDRINE; DOXORUBICIN; GLYCOPROTEIN P INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZYLISOQUINOLINE DERIVATIVE; EMULSION; LIPID; TETRANDRINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER RESISTANCE; CELL DEATH; DRUG CYTOTOXICITY; DRUG RELEASE; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TUMOR LEVEL; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MCF 7 CELL LINE; MOUSE; MULTIDRUG RESISTANCE; NANOEMULSION; NANOENCAPSULATION; NONHUMAN; TUMOR XENOGRAFT; ANIMAL; BREAST NEOPLASMS; CANCER TRANSPLANTATION; CHEMISTRY; DRUG RESISTANCE; EMULSION; NANOMEDICINE; NECROSIS; NUDE MOUSE; PROCEDURES; RAT; TISSUE DISTRIBUTION; TUMOR CELL LINE; WISTAR RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZYLISOQUINOLINES; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; EMULSIONS; FEMALE; HUMANS; LIPIDS; MICE; MICE, NUDE; NANOMEDICINE; NECROSIS; NEOPLASM TRANSPLANTATION; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 84920432220     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500637b     Document Type: Article

References (32)

1. Krishnamurthy, S.; Ng, V. W.; Gao, S.; Tan, M.-H.; Yang, Y. Y. Phenformin-loaded polymeric micelles for targeting both cancer cells and cancer stem cells in vitro and in vivo Biomaterials 2014, 35 (33) 9177-9186
2. Li, X.; Xu, H.; Dai, X.; Zhu, Z.; Liu, B.; Lu, X. Enhanced in vitro and in vivo therapeutic efficacy of codrug-loaded nanoparticles against liver cancer Int. J. Nanomed. 2012, 7, 5183
3. th ed.; Lippincott Williams & Wilkins: Philadelphia, 2003; pp 561-580.
4. Wong, H. L.; Bendayan, R.; Rauth, A. M.; Xue, H. Y.; Babakhanian, K.; Wu, X. Y. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system J. Pharmacol. Exp. Ther. 2006, 317 (3) 1372-1381
5. Gottesman, M. M.; Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter Annu. Rev. Biochem. 1993, 62 (1) 385-427
6. Jin, J.; Wang, F. P.; Wei, H.; Liu, G. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine Cancer Chemother. Pharmacol. 2005, 55 (2) 179-188
7. Kunjachan, S.; Rychlik, B.; Storm, G.; Kiessling, F.; Lammers, T. Multidrug resistance: physiological principles and nanomedical solutions Adv. Drug Delivery Rev. 2013, 65 (13) 1852-1865
8. Staudinger, R.; Knaus, H.-G.; Glossmann, H. Positive heterotropic allosteric regulators of dihydropyridine binding increase the Ca2+ affinity of the L-type Ca2+ channel. Stereoselective reversal by the novel Ca2+ antagonist BM 20.1140 J. Biol. Chem. 1991, 266 (17) 10787-10795
9. Wei, N.; Sun, H.; Wang, F.; Liu, G. H1, a novel derivative of tetrandrine reverse P-glycoprotein-mediated multidrug resistance by inhibiting transport function and expression of P-glycoprotein Cancer Chemother. Pharmacol. 2011, 67 (5) 1017-1025
10. Xiao, S. H.; Wei, G. L.; Lu, R.; Liu, C. X.; Wang, F. P. Studies on pharmacokinetics of bromotetrandrine in animals (II). Effect on interaction of bromoisotetrandrine and adriamycin on pharmacokinetics Asian J. Drug Metabol. Pharmacol. 2004, 4 (4) 61-64
11. Zheng, L.; Qing, Y.-p.; Xu, N.; Yu, Q.; Wang, Y.; Wang, F. P.; Li, Z.-y. Pharmacokinetics and safety of bromotetrandrine (BrTet, W198) after single-dose intravenous administration in healthy Chinese volunteers J. Clin. Pharm. Ther. 2010, 35 (1) 113-119
12. Gottesman, M. M. Mechanisms of cancer drug resistance Annu. Rev. Med. 2002, 53 (1) 615-627
13. Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol. Rev. 2004, 56 (2) 185-229
14. Zhang, X.; Sun, X.; Li, J.; Zhang, X.; Gong, T.; Zhang, Z. Lipid nanoemulsions loaded with doxorubicin-oleic acid ionic complex: characterization, in vitro and in vivo studies Pharmazie 2011, 66 (7) 496-505
15. Zhou, J.; Zhang, X.; Li, M.; Wu, W.; Sun, X.; Zhang, L.; Gong, T. Novel lipid hybrid albumin nanoparticle greatly lowered toxicity of pirarubicin Mol. Pharmaceutics 2013, 10 (10) 3832-3841
16. Santos-Magalhães, N.; Pontes, A.; Pereira, V.; Caetano, M. Colloidal carriers for benzathine penicillin G: nanoemulsions and nanocapsules Int. J. Pharm. 2000, 208 (1-2) 71-80
17. Zhao, D.; Gong, T.; Fu, Y.; Nie, Y.; He, L.-L.; Liu, J.; Zhang, Z.-R. Lyophilized Cheliensisin A submicron emulsion for intravenous injection: Characterization, in vitro and in vivo antitumor effect Int. J. Pharm. 2008, 357 (1) 139-147
18. Sonneville-Aubrun, O.; Simonnet, J.-T.; Lalloret, F. Nanoemulsions: a new vehicle for skincare products Adv. Colloid Interface Sci. 2004, 108, 145-149
19. Yilmaz, E.; Borchert, H.-H. Design of a phytosphingosine-containing, positively-charged nanoemulsion as a colloidal carrier system for dermal application of ceramides Eur. J. Pharm. Biopharm. 2005, 60 (1) 91-98
20. Mou, D.; Chen, H.; Du, D.; Mao, C.; Wan, J.; Xu, H.; Yang, X. Hydrogel-thickened nanoemulsion system for topical delivery of lipophilic drugs Int. J. Pharm. 2008, 353 (1) 270-276
21. Singh, K. K.; Vingkar, S. K. Formulation, antimalarial activity and biodistribution of oral lipid nanoemulsion of primaquine Int. J. Pharm. 2008, 347 (1) 136-143
22. Vyas, T. K.; Shahiwala, A.; Amiji, M. M. Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations Int. J. Pharm. 2008, 347 (1) 93-101
23. Bali, V.; Ali, M.; Ali, J. Study of surfactant combinations and development of a novel nanoemulsion for minimising variations in bioavailability of ezetimibe Colloids Surf., B 2010, 76 (2) 410-420
24. Sznitowska, M.; Zurowska-Pryczkowska, K.; Janicki, S.; Järvinen, T. Miotic effect and irritation potential of pilocarpine prodrug incorporated into a submicron emulsion vehicle Int. J. Pharm. 1999, 184 (1) 115-120
25. Costa, F.; Sousa, J.; Pais, A.; Formosinho, S. Comparison of dissolution profiles of ibuprofen pellets J. Controlled Release 2003, 89 (2) 199-212
26. Lv, S.; Tang, Z.; Li, M.; Lin, J.; Song, W.; Liu, H.; Huang, Y.; Zhang, Y.; Chen, X. Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer Biomaterials 2014, 35 (23) 6118-6129
27. Li, N.; Yi, Q.; Luo, K.; Guo, C.; Pan, D.; Gu, Z. Amphiphilic peptide dendritic copolymer-doxorubicin nanoscale conjugate self-assembled to enzyme-responsive anti-cancer agent Biomaterials 2014, 35 (35) 9529-9545
28. Lee, H. J.; Liu, Y.; Zhao, J.; Zhou, M.; Bouchard, R. R.; Mitcham, T.; Wallace, M.; Stafford, R. J.; Li, C.; Gupta, S.; Melancon, M. P. In vitro and in vivo mapping of drug release after laser ablation thermal therapy with doxorubicin-loaded hollow gold nanoshells using fluorescence and photoacoustic imaging J. Controlled Release 2013, 172 (1) 152-158
29. Krishna, R.; McIntosh, N.; Riggs, K. W.; Mayer, L. D. Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion Clin. Cancer Res. 1999, 5 (10) 2939-2947
30. Smith, L. A.; Cornelius, V. R.; Plummer, C. J.; Levitt, G.; Verrill, M.; Canney, P.; Jones, A. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials BMC Cancer 2010, 10 (1) 337
31. Shuhendler, A.; Prasad, P.; Zhang, R. X.; Amini, M.; Sun, M.; Liu, P.; Bristow, R. G.; Rauth, A. M.; Wu, X. Y. Synergistic Nanoparticulate Drug Combination Overcomes Multidrug Resistance, Increases Efficacy, and Reduces Cardiotoxicity in a Nonimmunocompromised Breast Tumor Model Mol. Pharmaceutics 2014, 11 (8) 2659-2674
32. Kim, J.-E.; Yoon, I.-S.; Cho, H.-J.; Kim, D.-H.; Choi, Y.-H.; Kim, D.-D. Emulsion-based colloidal nanosystems for oral delivery of doxorubicin: Improved intestinal paracellular absorption and alleviated cardiotoxicity Int. J. Pharm. 2014, 464 (1) 117-126